Absci Corp’s Chief Innovation Officer, Andreas Busch, reported an automatic share withholding related to equity compensation. On February 3, 2026, 1,469 shares of common stock were withheld by the company at $2.99 per share to satisfy tax obligations from vesting restricted stock units.
Following this tax-withholding event, Busch beneficially owns 322,703 shares of Absci common stock directly. According to the footnote, this transaction did not represent a discretionary trade or open-market sale by the insider.
Absci Corp’s Chief Executive Officer and director Sean McClain reported a transaction involving company common stock. On 02/02/2026, 26,761 shares at $2.99 per share were withheld by Absci to satisfy tax obligations tied to vesting restricted stock units, rather than being sold at his discretion. Following this withholding, McClain directly beneficially owned 8,334,567 common shares of Absci.
Absci Corp executive Jonasson Zachariah, the company’s CFO/CBO, reported a tax-related share withholding on February 2, 2026. Absci withheld 17,496 shares of common stock at $2.99 per share to cover tax obligations arising from the vesting of restricted stock units, which the filing states was not a discretionary trade. After this withholding, Zachariah directly beneficially owned 383,538 shares of Absci common stock.
Absci Corp officer Todd Bedrick reported an automatic share withholding related to equity compensation. On 02/02/2026, 3,659 shares of common stock at $2.99 per share were withheld by Absci to cover tax obligations from vesting restricted stock units. After this tax withholding, Bedrick directly beneficially owned 172,624 common shares. The footnote clarifies this was not a discretionary trade or open-market sale by the reporting person.
Absci Corporation reported that senior vice president and chief accounting officer Todd Bedrick received new equity awards on January 28, 2026. He was granted 15,000 shares of Common Stock in the form of restricted stock units at a price of $0, increasing his directly held Common Stock to 176,283 shares.
Bedrick was also granted a stock option for 59,400 shares of Common Stock at an exercise price of $2.94 per share, expiring on January 27, 2036. Both the RSUs and the option vest in three substantially equal annual installments starting on January 10, 2027, subject to his continuous service with Absci.
The Vanguard Group has filed a Schedule 13G reporting beneficial ownership of 7,910,205 shares of Absci Corp common stock, representing 5.26% of the class as of 12/31/2025.
Vanguard reports shared voting power over 996,166 shares and shared dispositive power over 7,910,205 shares, with no sole voting or dispositive power. The filing states these securities are held in the ordinary course of business and not for changing or influencing control of Absci. Vanguard notes an internal realignment effective 01/12/2026, after which certain subsidiaries may report beneficial ownership separately while continuing the same investment strategies.
Absci Corporation reported that it will present a business update at the 44th Annual J.P. Morgan Healthcare Conference on January 14, 2026. The company has prepared a slide presentation for this event and made it part of its official disclosures.
The slides from Absci's conference presentation are filed as Exhibit 99.1 and are also available on the investor relations section of its website under “Events and Presentations.” This gives investors and analysts access to the same materials being shown at the healthcare conference.
Absci Corporation reported third‑quarter 2025 results. Partner program revenue was $0.378 million, down from $1.701 million a year ago, reflecting milestone timing and program mix. The company posted a net loss of $28.7 million (basic and diluted loss per share $0.20) on total operating expenses of $30.5 million, including $19.2 million in R&D. For the first nine months, revenue was $2.15 million and net loss was $85.6 million.
Liquidity remained solid with $152.5 million in cash, cash equivalents and marketable securities as of September 30, 2025. The company strengthened its balance sheet in 2025 through a $20.0 million PIPE with AMD, a July offering yielding $46.7 million in net proceeds, and $35.7 million via a prior ATM program. Shares outstanding were 150,371,531 as of October 31, 2025.
Program updates: ABS‑101 Phase 1 in healthy volunteers showed extended half‑life versus first‑generation anti‑TL1A programs with a favorable safety profile; Absci plans to seek a partner after trial completion. ABS‑201 received HREC approval in Australia, with first dosing targeted for December 2025. A subsequent event settled Totient contingent consideration for approximately $7.6 million and released $8.7 million from escrow.
Absci Corporation announced its financial results for the third quarter ended September 30, 2025. The company furnished a press release as Exhibit 99.1 under Item 2.02, and noted that this information is being furnished and not deemed filed under the Exchange Act.
Absci also filed a Fall 2025 corporate presentation as Exhibit 99.2, which includes internal pipeline program updates and is available in the News & Events section of its website.
Absci Corporation entered into a Letter Agreement with SBGH, LLC that amends the 2021 Totient merger terms and sets a final distribution of milestone consideration. The agreement provides that certain former Totient stockholders will receive approximately $7.6 million, and Absci will receive approximately $8.7 million, in full satisfaction of all potential milestone payments under the merger agreement.
The Letter Agreement, dated October 31, 2025, is filed as an exhibit, with certain portions redacted as immaterial and confidential.